391 related articles for article (PubMed ID: 32232912)
21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
22. Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.
Liang X; Guo W; Ren T; Huang Y; Sun K; Zhang H; Yu Y; Wang W; Niu J
Cancer Lett; 2020 Jun; 480():4-14. PubMed ID: 32220541
[TBL] [Abstract][Full Text] [Related]
23. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
24. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
26. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W
Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
28. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
[TBL] [Abstract][Full Text] [Related]
29. Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model.
Le T; Su S; Shahriyari L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440778
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
[TBL] [Abstract][Full Text] [Related]
31. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
32. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
33. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.
Reddy SM; Reuben A; Barua S; Jiang H; Zhang S; Wang L; Gopalakrishnan V; Hudgens CW; Tetzlaff MT; Reuben JM; Tsujikawa T; Coussens LM; Wani K; He Y; Villareal L; Wood A; Rao A; Woodward WA; Ueno NT; Krishnamurthy S; Wargo JA; Mittendorf EA
Cancer Immunol Res; 2019 Jun; 7(6):1025-1035. PubMed ID: 31043414
[TBL] [Abstract][Full Text] [Related]
34. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
König L; Mairinger FD; Hoffmann O; Bittner AK; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A
BMC Cancer; 2019 Feb; 19(1):120. PubMed ID: 30717704
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
[TBL] [Abstract][Full Text] [Related]
36. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
37. Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes.
Yahiro K; Matsumoto Y; Yamada H; Endo M; Setsu N; Fujiwara T; Nakagawa M; Kimura A; Shimada E; Okada S; Oda Y; Nakashima Y
Cancer Immunol Immunother; 2020 May; 69(5):745-758. PubMed ID: 32047957
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death 2 functions as a tumor suppressor in osteosarcoma.
Yang Y; Jin Y; Du W
Int J Clin Exp Pathol; 2015; 8(9):10894-900. PubMed ID: 26617804
[TBL] [Abstract][Full Text] [Related]
39. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
40. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
